Beam Therapeutics, Inc. ( (BEAM) ) has released its Q3 earnings. Here is a breakdown of the information Beam Therapeutics, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Beam Therapeutics, Inc., a biotechnology company based in Cambridge, Massachusetts, focuses on developing precision genetic medicines through its base editing technology to provide life-long cures for genetic diseases. The company operates in the biotechnology sector and is committed to advancing its portfolio of programs and maintaining a strong intellectual property position.
In its latest earnings report for the quarter ended September 30, 2025, Beam Therapeutics reported a net loss of $112.7 million, compared to a net loss of $96.7 million in the same period last year. The company continues to invest heavily in research and development, with expenses reaching $109.8 million for the quarter, reflecting its commitment to advancing its clinical trials and research programs.
Key financial highlights include total revenue of $9.7 million from license and collaboration agreements, a decrease from $14.3 million in the previous year. Beam’s cash, cash equivalents, and marketable securities totaled $1.1 billion, providing a substantial runway for continued operations and development efforts. The company also raised $470.5 million through a public offering earlier in the year, strengthening its financial position.
Looking ahead, Beam Therapeutics remains focused on progressing its clinical trials, including those for BEAM-101, BEAM-302, and BEAM-301, as well as expanding its delivery modalities and partnerships. The company anticipates continued operating losses as it invests in research and development, but its strong cash position provides a solid foundation for future growth and innovation.